Jian Irish

Insider Reports History

Reporting-owner location: Emeryville, CA
Latest reporting-owner signature: /s/ Matthew L. Wein, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Jian Irish

Form 4 holding President and Chief Executive Officer, Director

Metagenomi Therapeutics, Inc.

Security class: Common Stock
Shares / value: 375,393
Estimated value: $434,855
Report date: 08 Sep 2026
Price: $1.16
Ownership: Direct

Form 4 holding President and Chief Executive Officer, Director

Metagenomi Therapeutics, Inc.

Security class: Common stock
Shares / value: 292,713
Estimated value: $348,328
Report date: 08 Sep 2026
Price: $1.19
Ownership: By Trust

Form 4 holding President and Chief Executive Officer, Director

Metagenomi Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 276,000
Estimated value
Report date: 01 Apr 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Jian Irish

4 MGX

Metagenomi Therapeutics, Inc.

Report period: 08 Sep 2026
Transactions: 1
Transaction value: -$2,479
Accepted by SEC: 10 Sep 2026, 15:40
Role: President and Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi Therapeutics, Inc.

Report period: 05 Jun 2026
Transactions: 1
Transaction value: -$4,854
Accepted by SEC: 10 Jun 2026, 11:21
Role: President and Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi Therapeutics, Inc.

Report period: 01 Apr 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Apr 2026, 14:11
Role: Title: President and Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi Therapeutics, Inc.

Report period: 05 Dec 2025
Transactions: 2
Transaction value: -$2,571
Accepted by SEC: 09 Mar 2026, 17:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi, Inc.

Report period: 05 Dec 2025
Transactions: 1
Transaction value: -$2,839
Accepted by SEC: 08 Dec 2025, 13:38
Role: Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi, Inc.

Report period: 05 Sep 2025
Transactions: 4
Transaction value: +$394,700
Accepted by SEC: 01 Dec 2025, 19:28
Role: Chief Executive Officer, Director
Next action: Open filing details

4 MGX

Metagenomi, Inc.

Report period: 06 Jun 2025
Transactions: 1
Transaction value: -$11,182
Accepted by SEC: 09 Jun 2025, 18:20
Role: Title: President and Chief Operating Officer, Director
Next action: Open filing details

4 MGX

Metagenomi, Inc.

Report period: 01 Apr 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Apr 2025, 11:57
Role: Title: President and Chief Operating Officer, Director
Next action: Open filing details

4 MGX

Metagenomi, Inc.

Report period: 01 Apr 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Apr 2024, 21:10
Role: Title: President and Chief Operating Officer, Director
Next action: Open filing details

3 MGX

Metagenomi Technologies, LLC

Report period: 08 Feb 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 08 Feb 2024, 19:11
Role: Title: President and Chief Operating Officer; Exhibit 24 - Power of Attorney, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .